Department of Respiratory Medicine, Yokohama Municipal Citizen's Hospital, Yokohama, Japan
Department of Respiratory Medicine, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.
Anticancer Res. 2020 Feb;40(2):923-928. doi: 10.21873/anticanres.14025.
BACKGROUND/AIM: We assessed the efficacy of immune checkpoint inhibitors (ICIs) in older patients because of the limited information regarding these patients.
We retrospectively analyzed 66 consecutive patients ≥70 years old with advanced non-small cell lung cancer (NSCLC). A total of 31 patients received ICIs (ICIs group) and 35 patients received only cytotoxic regimens (No ICIs group).
Patients with squamous cell carcinoma who received ICIs had better overall survival (OS) than those who did not (9.7 versus 4.7 months, p=0.027). In multivariate analysis, treatment with ICIs [hazard ratio (HR)=0.54, 95% confidence interval (CI)=0.30-0.98, p=0.044], good performance status (HR=0.30, 95%CI=0.16-0.57, p=0.0003), and histology other than squamous cell carcinoma (HR=0.41, 95%CI=0.19-0.83, p=0.014) were significantly favorable factors for OS.
ICIs may be effective for older patients with NSCLC, especially squamous cell carcinoma patients.
背景/目的：由于缺乏关于老年患者的相关信息，我们评估了免疫检查点抑制剂（ICI）在老年患者中的疗效。
我们回顾性分析了 66 例年龄≥70 岁的晚期非小细胞肺癌（NSCLC）患者。其中 31 例患者接受了 ICI 治疗（ICI 组），35 例患者仅接受了细胞毒性治疗方案（无 ICI 组）。
接受 ICI 治疗的鳞状细胞癌患者的总生存期（OS）优于未接受 ICI 治疗的患者（9.7 个月 vs. 4.7 个月，p=0.027）。多因素分析显示，ICI 治疗[风险比（HR）=0.54，95%置信区间（CI）=0.30-0.98，p=0.044]、良好的体能状态（HR=0.30，95%CI=0.16-0.57，p=0.0003）和非鳞状细胞癌组织学类型（HR=0.41，95%CI=0.19-0.83，p=0.014）是 OS 的显著有利因素。
ICI 可能对老年 NSCLC 患者有效，尤其是鳞状细胞癌患者。
